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Background. Persistence of plasma HIV-1 RNA during seemingly effective antiretroviral thereapy (ART) is incompletely under-
stood. Using an ultrasensitive assay, this cross-sectional study investigated residual plasma HIV-1 RNA in subjects maintained on 
firstline ART with continuous viral load suppression <50 copies/mL for ≤15 years without recognized viral load blips or treatment 
interruptions and explored its relationship with the duration of suppressive ART, efavirenz concentrations in plasma, 2-LTR circular 
HIV-1 DNA (2-LTRc DNA) in peripheral blood mononuclear cells, and cellular (CD4 plus CD26/CD38/CD69; CD8 plus CD38/
HLA-DR/DP/DQ) and soluble (sCD14, sCD27, sCD30, IL-6) markers of immune activation in peripheral blood. 
Methods. Residual plasma HIV-1 RNA, total HIV-1 DNA and 2-LTRc DNA were quantified by real-time and digital droplet 
PCR. Cellular (CD4 plus CD26/CD38/CD69; CD8 plus CD38/HLA-DR/DP/DQ) and soluble (sCD14, sCD27, sCD30, IL-6) mark-
ers of immune activation were measured by flow cytometry and ELISA.
Results. Residual plasma HIV-1 RNA and 2-LTRc DNA were detected in 52/104 (50%) and 24/104 (23%) subjects, respectively. 
Among subjects with detectable HIV-1 RNA, 50/52 showed levels ≤11 copies/mL. In adjusted analyses, HIV-1 RNA levels were 0.37 
log10 copies/mL higher with each log10 U/mL increase in sCD27 (95% confidence interval, 0.01–0.73; P = .02). No significant associ-
ation was found between residual plasma HIV-1 RNA and other explored parameters. 
Conclusions. These findings point to an ongoing relationship between plasma HIV-1 RNA and selected markers of immune 
activation during continuously suppressive ART. The novel direct association with levels of sCD27 warrants further investigation.
Keywords. 2-LTR circular DNA; activation; drug concentration; sCD27; viral load. 
Maintaining plasma HIV-1 RNA suppression below the limit of 
detection of commercial viral load assays defines clinical suc-
cess of antiretroviral therapy (ART) [1, 2]. Ultrasensitive assays 
can detect traces of HIV-1 RNA in the plasma of many success-
fully treated patients [3], but the source remains controversial 
[4, 5]. On the one hand, it is proposed that detection of residual 
plasma HIV-1 RNA reflects short-lived bursts of virus produc-
tion from latently infected memory CD4 T cells, but with ongo-
ing virus replication and genetic evolution inhibited by ART [6]. 
An alternative model derives from evidence of ongoing virus 
replication in compartments where drug penetration or activ-
ity is suboptimal [7–10]. While the 2 models are not mutually 
exclusive, published studies have often included patients with 
heterogeneous treatment histories and varying definitions of 
suppression, which may in part explain conflicting findings 
[11–13].
Identifying the determinants of HIV-1 RNA persistence 
during seemingly effective ART is central to our understand-
ing of how the virus may be eradicated [14, 15]. Such studies 
must also consider the interplay between virus replication and 
host immunity, and the role of chronic immune activation and 
inflammation in disease pathogenesis [16–18]. Effective ART 
reduces but does not always normalize inflammatory mark-
ers, raising the possibility that residual immune activation may 
both sustain and be sustained by residual virus replication [18]. 
Available data are not conclusive, however, and they rather point 
to virologic and immunologic events that take place before the 
initiation of ART as key determinants of the HIV-1 reservoirs 
and immune activation that can persist despite ART [19].
We previously reported that treated patients with plasma 
HIV-1 RNA detected at levels ranging between approximately 
10 and 49 copies/mL by a commercial viral load assay were more 
likely to experience viral load rebound above 50 copies/mL and 
above 400 copies/mL during 12  months of follow-up when 
compared with treated patients with undetectable HIV-1 RNA 
[20]. The aim of this study was to take the converse approach 
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and assess a population that experienced continuous viral load 
suppression <50 copies/mL for up to 15 years of firstline ART 
and use ultrasensitive testing to detect HIV-1 RNA below the 
10-copies/mL cutoff. The cohort was selected according to pre-
cise inclusion criteria, and residual plasma HIV-1 RNA was 
investigated cross-sectionally in relation to the duration of sup-
pressive ART, plasma concentrations of efavirenz, 2-LTRc DNA 
in peripheral blood mononuclear cells (PBMCs), and cellular 
and soluble markers of immune activation in peripheral blood.
METHODS
Study Population
In this cross-sectional study, eligible patients had started firstline 
ART with 2 nucleoside/nucleotide reverse transcriptase inhibi-
tors (NRTIs) plus 1 non-nucleoside reverse transcriptase inhib-
itor (NNRTI), had achieved viral load suppression <50 copies/
mL within 6 months of starting ART, and during subsequent fol-
low-up had remained on the initial NNRTI, undergone ≥2 viral 
load measurements per year, and maintained continuous viral 
load suppression <50 copies/mL without any recorded viral load 
elevation >50 copies/mL or treatment interruption. To ensure 
balance in terms of duration of suppressive ART, recruitment was 
stratified to span from 1 year of treatment to 10 years or longer. 
Changes of the initial NNRTI were not allowed. Changes of 
the initial NRTIs were allowed to reflect evolving practice, pro-
vided they did not coincide with a viral load >50 copies/mL or a 
treatment interruption. The study took place at multiple centers 
across the United Kingdom. It was approved by the National 
Research Ethics Service (London-Dulwich) and included in the 
National Institute for Health Research Clinical Research Network 
Portfolio. Patients provided written informed consent.
Residual Plasma HIV-1 RNA
Plasma was separated from venous blood in EDTA within 2 
hours of collection and stored at −80°. HIV-1 RNA was quan-
tified using a modified version of the RealTime HIV-1 assay 
(Abbott, Maidenhead, UK). Validation studies previously 
showed that the assay 50% and 95% detection rates were 1 and 3 
HIV-1 RNA copies/mL, respectively, with high reproducibility 
across diverse HIV-1 subtypes [10, 20, 21].
Total HIV-1 DNA and 2-LTRc DNA
PBMCs were isolated by Ficoll-Hypaque gradient centrifuga-
tion and cryopreserved. Total HIV-1 DNA was quantified by 
real-time polymerase chain reaction (PCR) as described [22]; 
the assay 50% and 95% detection rates were 20 and 40 HIV-1 
DNA copies/106 PBMC, respectively. 2-LTRc DNA was meas-
ured by droplet digital PCR as described [23]; the assay’s lower 
limit of detection was a median (interquartile range [IQR]) of 5 
(4–6) copies/106 PBMC. 
Cellular and Soluble Markers of Immune Activation
Flow cytometry was performed at the Immunology Service of 
the Royal Free Hospital in London using freshly collected blood. 
Following centrifugation, cell pellets were lysed by 10-minute 
incubation at room temperature in 1× Hoffman’s lysis buffer 
and incubated with FITC-, Cy5- or PE-labeled antibodies tar-
geting CD4 plus CD26, CD38, or CD69, and CD8 plus CD38 or 
HLA-DR/DP/DQ (Becton Dickinson, Swindon, UK). Labeled 
cells were incubated in 1% paraformaldehyde for 30 minutes 
prior to acquisition with BD FACSCalibur and analysis by 
CellQuest. Soluble markers were measured in frozen plasma 
by commercial Elisa assays (EIAs) for soluble CD14 (sCD14, 
R&D system, London, UK; assay sensitivity ≥125 ×  10−6 µg/
mL), soluble CD27 (sCD27, EBiosciences; ThermoFisher, 
Loughborough, UK; assay sensitivity ≥0.2 U/mL), soluble CD30 
(sCD30, EBiosciences, UK; assay sensitivity ≥0.3 ng/mL), and 
IL6 (EBiosciences, UK, assay sensitivity ≥0.9 pg/mL).
Plasma Drug Concentrations
Efavirenz (EFV) and nevirapine (NVP) concentrations were 
measured in untimed plasma samples using high-performance 
liquid chromatography–tandem mass spectrometry, as previ-
ously described [10]. The time of sample collection relative to 
last dosing was recorded.
Analysis
Duration of suppressive ART was defined as the length of time 
following the first viral load measurement <50 copies/mL, which 
in all subjects was recorded within 6  months of starting ART. 
When analyzing residual plasma HIV-1 RNA and 2-LTRc DNA 
as continuous variables, undetectable values were replaced with 
the midpoint value between 0 and the lower limit of detection 
of the assays. EFV and NVP concentrations were categorized as 
above or below the recommended minimal effective concentra-
tion (MEC) for wild-type virus: 1000 ng/mL for EFV [24] and 
3400 ng/mL for NVP [25]. Participants’ characteristics were com-
pared by analysis of variance (ANOVA), the Kruskal-Wallis test, 
and the Fisher exact test for continuous and categorical variables, 
as appropriate. Data distribution was assessed through descrip-
tive scatter plots. The correlation between EFV concentrations 
and levels of residual plasma HIV-1 RNA and 2-LTRc DNA was 
measured by Spearman’s rank test. Given that all but 2 HIV-1 
RNA values were ≤11 copies/mL, in order to reduce heterogene-
ity, the main statistical models excluded 2 subjects with residual 
plasma HIV-1 RNA >11 copies/mL (referred to as outliers). This 
was based on our previous data indicating that patients on stable 
ART with a viral load above approximately 10 copies/mL are a 
distinct population at risk of viral load rebound [20]. Three main 
models were run. The mean difference (with 95% confidence 
interval [CI]) in residual plasma HIV-1 RNA, total HIV-1 DNA, 
2-LTRc DNA, and markers of immune activation according to 
duration of suppressive ART (normalized over 1 year) was ana-
lyzed by univariable linear regression analysis after log-transfor-
mation of the variables. Factors associated with levels of residual 
plasma HIV-1 RNA or 2-LTRc DNA were investigated by uni-
variable and multivariable linear regression analysis. Variables 
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associated (P ≤ .20) with the outcome of interest in the univaria-
ble analysis were included in the multivariable models, with the 
following modifications: (a) when modeling 2-LTRc DNA, total 
HIV-1 DNA was excluded due to high colinearity (P <  .0001); 
(b) age and duration of ART were excluded in favor of duration 
of suppressive ART. Separate models explored: (a) the effect of 
forcing the nadir CD4 cell count and pre-ART viral load into the 
multivariable analyses and (b) the association between residual 
plasma HIV-1 RNA or 2-LTRc DNA and plasma concentrations 
of EFV (as a continuous variable) in EFV recipients, after adjust-
ment for the time of sampling in relation to the last EFV dose. 
IBM SPSS v. 22.0 (Armonk, NY, USA) and SAS v9.4 (Cary, NC, 
USA) were used for the analyses.
RESULTS
Study Population
The population comprised 104 patients that at the time of 
recruitment had experienced continuous viral load suppression 
<50 copies/mL for a median (IQR) of 5 (3–8) years while receiv-
ing firstline ART with 2 NRTIs plus either EFV (n = 86, 83%) 
or NVP (Table 1). Reflecting evolving guidelines about when to 
start ART and which antiretrovirals to use, patients with longer 
duration of suppressive ART had a lower nadir CD4 cell count 
and a higher pre-ART viral load, were more often receiving 
NVP, and were more likely to have experienced changes of the 
NRTI backbone after first starting ART: 48/104 (48%) patients 
changed ≥1 NRTIs prior to recruitment, with a median (IQR) of 
1 (1–2) NRTI change per subject. At recruitment, NRTI back-
bones comprised tenofovir disoproxil fumarate (78/104, 75%), 
abacavir (22/104, 21%) or zidovudine (4/104, 4%), plus emtric-
itabine or lamivudine.
Residual plasma HIV-1 RNA was detected in 52/104 (50%) 
patients (Table  1). Levels ranged between 1 and 35 copies/
mL and were ≤11 copies/mL in 50/52 (96%) patients; levels in 
the 2 outliers were 35 and 24 copies/mL after 2 and 3 years of 
suppressive ART, respectively (Figure 1). 2-LTRc HIV-1 DNA 
Table 1. Characteristics of the Study Population Overall and by Duration of Suppressive ART (n = 104)a
Total (n = 104)
Duration of Suppressive ART, y
<4 (n = 34) 4–7 (n = 35) >7 (n = 35)
Duration of suppressive ART, median (IQR), y 5 (3–8) 2 (2–3) 5 (5–6) 9 (8–10)
Age, median (IQR), y 47 (40–53) 44 (36–49) 49 (39–53) 48 (43–55)
Male, n (%) 81 (78) 29 (85) 29 (83) 23 (66)
Ethnicity, n (%) White 59 (57) 20 (59) 22 (63) 17 (49)
Black 41 (39) 13 (38) 11 (31) 17 (49)
Asian 4 (4) 1 (3) 2 (6) 1 (3)
Pre-ART viral load, median (IQR), log10 cps/mL 4.9 (4.6–5.3) 4.7 (4.1–5.1) 4.9 (4.6–5.3) 5.1 (4.8–5.6)
Nadir CD4 count, median (IQR), cells/mm3 201 (110–270) 279 (216–365) 166 (126–238) 118 (79–215)
EFV use, n (%) 86 (83) 30 (88) 32 (89) 24 (69)
NNRTI concentration, median (IQR), ng/mL EFV 1531 (846–2235) 1492 (735–2130) 1496 (866–2154) 1966 (855–2626)
NVP 5889 (3096–7419) 4545 (2798–6147) 2734 (2539–5743) 6311 (4390–7603)
NNRTI concentration above target MECb, n (%) 71 (66) 22 (65) 24 (69) 25 (71)
Changed initial NRTIs, n (%) 48 (46) 4 (12) 13 (37) 31 (89)
Detectable residual plasma HIV-1 RNA, n (%) 52 (50) 21 (62) 18 (51) 13 (37)
Residual plasma HIV-1 RNA, median (IQR),c cps/mL 2 (2–4) 2 (2–4) 2 (2–4) 2 (2–2)
Detectable 2-LTRc DNA, n (%) 24 (23) 12 (35) 7 (20) 5 (14)
2-LTRc DNA, median (IQR),d cps/106 PBMC 3 (3–3) 3 (3–7) 3 (3–3) 3 (3–3)
Total HIV-1 DNA, median (IQR), log10 cps/10
6 PBMC 2.5 (2.1–2.8) 2.6 (2.3–3.0) 2.4 (1.7–2.8) 2.5 (2.1–2.8)
CD4 count, median (IQR), cells/mm3 581 (474–722) 548 (427–629) 580 (509–720) 632 (503–796)
CD8 count, median (IQR), cells/mm3 798 (656–1047) 808 (596–1060) 818 (685–1024) 679 (496–929)
CD4+ CD38+, median (IQR), % 24 (16–34) 32 (23–36) 21 (15–31) 22 (15–28)
CD4+CD26+, median (IQR), % 58 (46–64) 56 (47–67) 59 (49–63) 58 (44–64)
CD4+CD69+, median (IQR), % 1 (1–2) 2 (1–3) 1 (1–2) 2 (1–2)
CD8+CD38+, median (IQR), % 5 (3–7) 6 (4–8) 4 (3–6) 4 (3–6)
CD8+HLA-DR/DP/DQ+, median (IQR), % 35 (24–42) 37 (27–47) 35 (26–40) 30 (20–39)
sCD14, median (IQR), µg/mL 2.2 (1.8–2.5) 2.2 (1.8–2.4) 2.0 (1.8–2.5) 2.3 (1.9–2.5)
sCD27, median (IQR), Ug/mL 62 (49–76) 64 (52–80) 61 (54–76) 60 (46–71)
sCD30, median (IQR), ng/mL 11 (9–15) 11 (9–15) 12(10–17) 11 (9–13)
IL6 median (IQR), pg/mL 0.8 (0.5–2.1) 0.5 (0.5–1.2) 1.1 (0.5–2.3) 0.8 (0.5–2.1)
Abbreviations: 2-LTRc DNA, 2-LTR circular HIV-1 DNA; ART, antiretroviral therapy; cps, copies; EFV, efavirenz; IQR, interquartile range; MEC, minimum effective concentration; NNRTI, non-nu-
cleoside reverse transcriptase inhibitor; NRTI, nucleoside/nucleotide reverse transcriptase inhibitor; NVP, nevirapine; PBMC, peripheral blood mononuclear cell.
aDefined as the length of time between the first viral load <50 copies/mL measured after starting ART and the date of recruitment.
bMinimum effective concentration recommended for wild-type virus (1000 ng/mL for EFV and 3400 ng/mL for NVP).
cSamples with undetectable HIV-1 RNA were assigned an arbitrary value of 1.5 copies/mL. 
dSamples with undetectable 2-LTRc DNA were assigned an arbitrary value of 2.5 copies/106 PBMC. 
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was detected in 24/104 (23%) patients with median levels of 3 
copies/106 PBMC that ranged between 4 and 119 copies/106 
PBMC (Figure 1). Cellular (Supplementary Figure 1) and sol-
uble (Figure 1; Supplementary Figure 2) markers of immune 
activation were detected in all patients. Levels of soluble mark-
ers were generally not dissimilar from those of HIV-negative 
volunteers reported in published studies [26–29]. When ana-
lyzing subjects whose levels of soluble markers fell above the 
upper quartile of the whole study population, a few patients 
presented concomitant elevations, but with little evidence 
of consistent patterns. Overall 5/104 (5%) patients showed 
concomitant elevations of >2 soluble markers, comprising 
sCD14 + sCD27 + sCD30 (3/104, 3%); CD27 + sCD30 + IL-6 
(1/104, 1%); and sCD14 + sCD27 + sCD30 + IL-6 (1/104, 1%) 
(Supplementary Table  1). CD8 cells counts and frequency of 
CD8+HLA-DR/DP/DQ+ cells were often, albeit not always, 
increased in these patients, but there were no apparent patterns 
in other parameters.
Virologic and Immunologic Parameters in Relation to the Duration of 
Suppressive ART
Differences in virologic and immunologic parameters 
according to the duration of suppressive ART, analyzed after 
exclusion of the 2 outliers, are shown in Table 2. Patients with 
longer duration of suppressive ART had higher CD4 counts 
(+19 cells/mm3/y) and lower expression of activation mark-
ers on CD4 cells (CD38) and CD8 cells (CD38, HLA-DR/
DP/DQ). Levels of sCD14, sCD30, and IL-6 did not differ by 
duration of suppressive ART, whereas levels of sCD27 were 
significantly lower with longer duration of suppressive ART. 
A trend was observed for lower levels of 2-LTRc DNA with 
longer duration of suppressive ART. There was less evidence 
of a difference in residual plasma HIV-1 RNA, and no sig-
nificant difference was seen in total HIV-1 DNA. A  linear 
regression analysis confirmed an inverse association between 
2-LTRc DNA and duration of suppressive ART, with an 
adjusted mean difference of 0.03 log10 copies/10
6 PBMC per 
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Figure 1. Virologic and immunologic parameters in patients with up to 15 years of consistently suppressive antiretroviral therapy (ART; n = 104), comprising (A) residual 
plasma HIV-1 RNA (copies/mL), (B) 2-LTR circular HIV-1 DNA (2-LTRc DNA; copies per 106 peripheral blood mononuclear cell [PBMC]), (C) total HIV-1 DNA (log10 copies per 
106 PBMC), and (D) sCD27 (U/mL) in relation to the duration of suppressive ART (years). In (D), the dotted line indicates the mean sCD27 levels reported in HIV-negative 
volunteers in published studies (164 U/mL) [25]; the solid lines indicate the median values measured in the whole study population. Each circle represents 1 participant; the 
2 solid squares represent the 2 patients with residual plasma HIV-1 RNA >11 copies/mL.
Downloaded from https://academic.oup.com/ofid/article-abstract/5/2/ofy032/4837293
by UCL (University College London) user
on 15 March 2018
Residual HIV-1 RNA During ART • OFID • 5
year longer (95% CI, –0.05 to –0.00; P = .02) (Supplementary 
Table 2). Forcing the nadir CD4 cell count and pre-ART viral 
load into the multivariable model did not change the find-
ings: 2-LTRc DNA levels were 0.03 log10 copies/10
6 PBMC 
lower per year of suppressive ART (95% CI, –0.05 to –0.00; 
P = .02; not shown).
Factors Associated With Residual Plasma HIV-1 RNA
The univariable linear regression analysis indicated a signif-
icant direct association between residual plasma HIV-1 RNA 
and sCD27 among the 102 subjects with HIV-1 RNA ≤11 cop-
ies/mL (Table  3). There was a weaker direct association with 
sCD30, whereas no association was evident with other markers 
of immune activation. There was also no association between 
residual plasma HIV-1 RNA and total HIV-1 DNA and 2-LTRc 
DNA. The direct association between residual plasma HIV-1 
RNA and sCD27 persisted after adjusting for the duration of 
suppressive ART, frequency of CD8+CD38+ cells, and levels of 
sCD30 and IL-6 (Table 3). There was no apparent association 
between residual plasma HIV-1 RNA and nadir CD4 cell count 
and pre-ART viral load in the univariable analysis. Forcing the 
nadir CD4 cell count and pre-ART viral load into the multivar-
iable model did not change the findings: residual plasma HIV-1 
RNA was 0.44 log10 copies/mL higher per each log10 increase 
in sCD27 (95% CI, 0.09–0.79; P =  .02; not shown). The asso-
ciation similarly persisted in analyses including the 2 outliers 
(not shown).
Relationship Between Virologic Parameters and Plasma Drug 
Concentrations
We first explored the association between plasma EFV concen-
trations and virologic parameters in 76 EFV recipients (includ-
ing the 2 outliers) who had taken the last EFV dose a median 
(IQR) of 12 (10–13) hours prior to sampling, and were there-
fore in the range of the “mid-dose” interval, where targets have 
been previously defined [30]. Although EFV concentrations 
Table  2. Univariable Analysis of the Mean Difference in Virologic and 
Immunologic Parameters per 1 Year of Suppressive ART (n = 102)a
Mean  
Differenceb 95% CI P
Residual plasma HIV-1 RNA,  
cps/mL
–0.013 –0.030 to 0.004 .12
2-LTRc DNA, cps/106 PBMC –0.018 –0.039 to 0.003 .09
Total HIV-1 DNA, cps/106 PBMC  0.004 –0.033 to 0.042 .82
CD4 count, cells/mm3  0.015  0.004 to 0.026 .01
CD8 count, cells/mm3 –0.004 –0.018 to –0.009 .52
CD4+CD38+, % –0.022 –0.034 to –0.009 .001
CD4+CD26+, % –0.003 –0.012 to 0.005 .44
CD4+CD69+, % –0.008 –0.021 to 0.005 .21
CD8+CD38+, % –0.014 –0.032 to 0.004 .05
CD8+HLA-DR/DP/DQ+, % –0.014 –0.027 to 0.001 .04
sCD14, µg/mL  0.002 –0.004 to 0.009 .50
sCD27, U/mL –0.010 –0.019 to 0.000 .05
sCD30, ng/mL –0.005 –0.019 to 0.009 .44
IL-6, pg/mL  0.003 –0.015 to 0.022 .72
Abbreviations: 2-LTRc DNA,  2-LTR circular HIV-1 DNA; CI,  confidence interval; 
PBMC, peripheral blood mononuclear cell.
aThe analysis excluded the 2 outliers with residual plasma HIV-1 RNA >11 copies/mL. 
bVariables were log-transformed prior to the analysis. 
Table 3. Univariable and Multivariable Linear Regression Analysis of Factors Associated With Mean Differences in Levels of Residual Plasma HIV-1 RNA 
(n = 102)a
Univariate Multivariablec
Mean Differenceb 95% CI P Mean Difference 95% CI P
Nadir CD4 count per 100 cell/mm3 higher  0.01 –0.06 to 0.05 .58
Pre-ART viral load per log10 cps/mL higher  0.00 –0.08 to 0.08 .99
Duration of suppressive ART per 1 y longer –0.01 –0.03 to 0.00 .12 –0.01 –0.02 to 0.01 .39
CD4 count per 100 cells/mm3 higher –0.01 –0.02 to 0.02 .92
CD4/CD8 ratio per 1 unit higher  0.04 –0.11 to 0.17 .62
2-LTRc DNA per log10 cps/10
6 PBMC higher  0.05 –0.11 to 0.20 .57
Total HIV-1 DNA per log10 cps/10
6 PBMC higher –0.01 –0.09 to 0.08 .87
CD4+CD38+ per 50% higher  0.08 –0.14 to 0.30 .47
CD4+CD26+ per 50% higher  0.08 –0.10 to 0.27 .37
CD4+CD69+ per 50% higher –0.61 –2.97 to 1.75 .60
CD8 count per 100 cells/mm3 higher  0.02 –0.01 to 0.01 .70
CD8+CD38+ per 50% higher  0.32 –0.11 to 0.75 .16  0.26 –0.17 to 0.68 .24
CD8+HLA-DR/DP/DQ+ per 50% higher –0.03 –0.21 to 0.15 .76
sCD14 per log10 µg /mL higher  0.26 –0.24 to 0.75 .31
sCD27 per log10 U/mL higher  0.49  0.17 to 0.81 .003  0.37  0.01 to 0.73 .02
sCD30 per log10 ng/mL higher  0.21 –0.02 to 0.45 .07  0.02 –0.25 to 0.28 .88
IL6 per log10 pg/mL higher  0.13 –0.05 to 0.30 .15  0.12 –0.06 to 0.29 .19
Abbreviations: 2-LTRc DNA, 2-LTR circular HIV-1 DNA; ART, antiretroviral therapy; CI, confidence interval; cps, copies; PBMC, peripheral blood mononuclear cell.
aThe analysis excluded the 2 outliers with residual plasma HIV-1 RNA >11 copies/mL. 
bMean difference in log10 copies/mL. 
cVariables with P < .2 in the univariable analysis were included in the multivariable analysis. 
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varied across patients, there was no clear correlation with levels 
of residual plasma HIV-1 RNA and 2-LTRc DNA (Spearman’s 
rank test) (Figure  2). Two separate linear regression analy-
ses explored the association between EFV concentrations and 
residual plasma HIV-1 RNA and 2-LTRc DNA among the 74 
patients with residual plasma HIV-1 RNA ≤11 copies/mL. In 
models that included both EFV concentration and timing of 
sampling relative to last EFV dose, there was no evidence of an 
association between plasma HIV-1 RNA (P  =  .30) or 2-LTRc 
DNA (P  =  .47) and EFV concentrations (Supplementary 
Table 3).
DISCUSSION
This study demonstrated that half of subjects who had expe-
rienced viral load suppression <50 copies/mL continuously 
for up to 15 years while maintained on the initial NNRTI had 
detectable HIV-1 RNA in plasma when tested with an ultra-
sensitive assay, at levels that rarely exceeded 11 copies/mL. We 
previously reported that in treated patients, plasma HIV-1 RNA 
levels above approximately 10 copies/mL were associated with 
a risk of viral load rebound above 50 copies/mL and above 400 
copies/mL over 12  months of follow-up [20]. Taken together, 
our findings suggest a cutoff level for plasma HIV-1 RNA below 
which a risk of viral load rebound is not observed. However, 
an independent, direct association persisted between residual 
plasma HIV-1 RNA and the immune activation marker sCD27 
in this stably treated population.
These data do not elucidate the debated source of residual 
plasma HIV-1 RNA [15, 31]. The lack of a correlation with lev-
els of 2-LTRc DNA, drug concentrations, or multiple markers 
of immune activation may indicate that ongoing virus replica-
tion was an unlikely source, as far as it can be extrapolated from 
measurements made in peripheral blood. In this context, the 
findings may provide support to the notion that during effect-
ive treatment, detection of a few HIV-1 RNA copies in plasma 
reflects transient bursts of virus production from latent reser-
voirs that are inhibited from ongoing replication by ART [8, 32]. 
In this model, a direct correlation may be anticipated between 
the likelihood of HIV-1 RNA persistence and the size of the 
viral reservoir. We did not detect an association between resid-
ual HIV-1 RNA in plasma and total HIV-1 DNA in PBMC, and 
we similarly did not previously observe an association with inte-
grated HIV-1 DNA in PBMC [21]. Findings from other studies 
are conflicting, possibly reflecting differences in the compos-
ition of the study populations (eg, proportion of patients on 
protease inhibitors) and the method used for measuring HIV-1 
RNA [33]. We also measured 2-LTRc DNA in PBMC as a pos-
sible indicator of viral gene expression and virus replication 
and found no correlation with residual plasma HIV-1 RNA. In 
a previous study of 30 subjects who had received various ART 
regimens for 7–12 years, 2-LTRc DNA was detected in 8 sub-
jects (27%) [33], which is highly comparable to our detection 
rate of 23%. In our study, 2-LTRc DNA levels were lower, with 
longer duration of suppressive ART, with a reduction of 0.02 
log10 2-LTRc DNA copies/10
6 PBMC per year. This apparent, 
slow decay in 2-LTRc DNA is consistent with observations from 
Bushman [34] and Siliciano [35], and potentially in line with 
the hypothesis that episomal HIV-1 DNA survives for the life 
of the cell, rather than being a short-lived product of ongoing 
virus replication [36].
Previous studies did not detect an association between 
residual plasma HIV-1 RNA and markers of immune activa-
tion on CD4 or CD8 cells (including CD38 and HLA-DR) in 
patients treated for up to 4 years [14, 37], and also detected no 
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Figure 2. Relationship between efavirenz (EFV) plasma concentrations and (A) residual plasma HIV-1 RNA and (B) 2-LTR circular HIV-1 DNA (2-LTRc DNA) among 76 patients 
who had taken the last EFV dose a median of 12 hours (interquartile range, 10–13) prior to sampling. Cutoffs in the x-axes represent the minimum effective concentration 
(MEC) recommended for wild-type virus (1000 ng/mL). The dotted black lines indicate the assay limit of detection (HIV-1 RNA = 3 copies/mL; 2-LTR DNA = 5 copies/106 
peripheral blood mononuclear cell). Each circle represents 1 participant; the 2 solid squares represent the 2 patients with residual plasma HIV-1 RNA >11 copies/mL.
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association with levels of sCD14 and IL-6 [19]. Our data con-
firm these observations over the longer term. However, we 
found that levels of sCD27 were independently associated with 
levels of residual plasma HIV-1 RNA. sCD27 is a 32-kD pro-
tein identical to the extracellular domain of CD27, a transmem-
brane protein and TNF receptor that is expressed on subsets of 
T, B, NK, and hematopoietic progenitor cells. sCD27 is released 
primarily from CD4 T cells and provides a costimulatory func-
tion that promotes activation and proliferation of T and B lym-
phocytes [38–41]. sCD27 can be detected in healthy donors, 
and increased plasma levels have been observed in conditions 
characterized by immune activation, especially auto-immune 
disorders [42–44]. There are limited data in the setting of HIV 
infection. Levels of sCD27 have been shown to be generally 
higher than in HIV-negative controls and found to be predic-
tive of the risk of HIV-related renal dysfunction and lympho-
mas [42, 45]. Levels have been shown to decline significantly in 
the first 12 to 24 months of ART and to increase again with viral 
load rebound or upon treatment discontinuation [29, 46, 47]. In 
our study, consistent with the reported effect of treatment, levels 
of sCD27 were overall low and reduced further with longer dur-
ation of suppressive ART. Taken in the context of these previous 
observations, our findings illustrate a close association between 
sCD27 and potential indicators of HIV replication during sup-
pressive ART that warrants further investigation.
There are scarce data on the effect of ART on sCD30 [26]. 
Levels in our population were considerably lower than those 
measured in the first 4 weeks of ART [48], and closer to levels 
published from HIV-negative volunteers [28]; however, sCD30 
showed no independent association with virologic parameters. 
Levels of sCD14, IL-6, and cellular markers of immune activa-
tion in our study population were comparable to those previ-
ously measured in HIV-1-positive patients receiving ART for 
up to 6  years [19, 49]. Consistent with previous observations 
(reviewed in [16]), markers of immune activation on CD4 
and CD8 cells (CD38 and HLA-DR/DP/DQ) were lower with 
longer duration of suppressive ART, and this apparent decline 
was paralleled by a predictable gain in CD4 cell counts. Overall, 
as also reported by Gandhi et al. [19], sCD14, IL6, and cellular 
markers of immune activation showed no apparent association 
with levels of residual plasma HIV-1 RNA and 2-LTRc DNA.
Our study has limitations. First, findings obtained in a 
cross-sectional study should be confirmed with prospectively 
collected data, which is challenging when aiming to study long-
term outcomes in populations maintained on the same regi-
men. To date, prospectively determined virologic indicators 
of HIV-1 persistence during long-term suppressive ART have 
been poorly documented. Compared with published studies 
addressing similar questions, one strength of our study is the 
relatively large population combined with stringent eligibility 
criteria and a consistent definition of virologic suppression. 
It could be argued that our study population was not selected 
based on the infection stage at the start of ART, which could 
have introduced a bias. We observed a lower nadir CD4 cell 
count and a higher pre-ART viral load in subjects with longer 
duration of suppressive ART; however, the analyses did not 
identify an effect of nadir CD4 cell count or pre-ART viral load 
on the measured parameters in our highly selected population. 
Of note, we excluded 2 outliers from the main analyses with 
residual plasma HIV-1 RNA levels >11 copies/mL. Whereas the 
main conclusions were not affected by their inclusion, it would 
have been of interest to determine any risk of viral load rebound 
with prospective follow-up in these 2 subjects. Further, we 
reported total HIV-1 DNA rather than integrated HIV-1 DNA 
as the indicator of the viral reservoir in this study. However, we 
previously described integrated HIV-1 DNA levels in a subset 
of the same population and demonstrated that they were highly 
correlated with the levels of total HIV-1 DNA, not influenced 
by the duration of suppressive ART, and not associated with 
residual HIV-1 RNA [21]. We collected large volumes of blood 
from patients in order to test for multiple parameters (eg, 8 mL 
of plasma was required for the ultrasensitive HIV-1 RNA assay 
alone). Limited sample volumes meant that not all potentially 
relevant immune parameters were measured. When selecting 
soluble markers of immune activation, we elected to include 2 
markers that have been extensively explored in the published 
literature (sCD14 and IL-6) to provide a reference and added 
2 markers for which there is high plausibility but scarce pub-
lished evidence (sCD27 and sCD30). In this context, levels of 
soluble markers of immune activation were found to be sim-
ilar to those historically reported in HIV-negative volunteers, 
which is consistent with the established beneficial effects of 
suppressive ART. However, published data from healthy volun-
teers were limited, especially for sCD27 and sCD30, and ideally, 
matched HIV-negative controls should be sampled to confirm 
reference values. As an additional point, we measured plasma 
NNRTI concentrations in untimed specimens and for practical 
reasons did not seek to obtain a measure of Ctrough. The patients 
analyzed in the models had taken the last EFV dose at a consist-
ent interval relative to sampling, and time of sampling would 
be expected to have little impact overall. Finally, we recognize 
that both drug concentration and antiviral activity measured in 
peripheral blood do not necessarily reflect the situation in lym-
phoid tissue [8, 9].
In conclusion, this study provides evidence that residual 
plasma HIV-1 RNA and PBMC-associated 2-LTRc DNA can 
be detected in a subset of patients receiving long-term, con-
tinuously suppressive firstline ART, without evidence of a clear 
association between the two, and without evidence of an asso-
ciation of either parameter with plasma concentrations of EFV. 
While residual plasma HIV-1 RNA was not associated with 
commonly reported markers of immune activation, there was 
a novel, independent direct association with levels of sCD27. 
Further studies are warranted to confirm the findings, extend 
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the immune activation profiling, and determine the underlying 
mechanism, including whether the relationship reflects ongo-
ing virus replication in lymphoid tissue.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases 
online. Consisting of data provided by the authors to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility of 
the authors, so questions or comments should be addressed to the corre-
sponding author.
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